Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines

Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines

Head and neck cancers (HNSCCs), especially in the advanced stages, are predominantly treated by radiochemotherapy, including cisplatin. The cure rates are clearly higher for HPV-positive HNSCCs when compared to HPV-negative HNSCCs. For both entities, this treatment is accompanied by serious adverse...

Full description

Saved in:
Bibliographic Details
Main Authors: Subtil, Florentine S. B., Gröbner, Carolin, Recknagel, Niklas, Parplys, Ann Christin, Kohl, Sibylla, Arenz, Andrea, Eberle, Fabian, Dikomey, Ekkehard, Engenhart-Cabillic, Rita, Schötz, Ulrike
Format: Article
Language:English
Published: Philipps-Universität Marburg 2023
Subjects:
Medizin
NVP-BEZ235
irradiation
cisplatin
clonogenic survival
HPV
HNSCC
radiosensitization
Medical sciences Medicine
Online Access:PDF Full Text
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

PDF Full Text

Holdings details from
Call Number: urn:nbn:de:hebis:04-es2023-00333
Publication Date: 2023-04-03
Source: Erstveröffentlichung: Subtil, F.S.B.; Gröbner, C.; Recknagel, N.; Parplys, A.C.; Kohl, S.; Arenz, A.; Eberle, F.; Dikomey, E.; Engenhart-Cabillic, R.; Schötz, U. Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines. Cancers 2022, 14, 3160. https://doi.org/10.3390/cancers14133160
Downloads: 62 (2024), 73 (2023)
License: https://creativecommons.org/licenses/by/4.0
Access URL: https://archiv.ub.uni-marburg.de/es/2023/0033
https://doi.org/10.3390/cancers14133160

Similar Items